Considering her tumor size and age, the patient accepted 4 cycles of concurrent TC chemotherapy (taxol/cyclophosphamide) and tamoxifen as adjuvant endocrine therapy because the invasive focus was strongly ER- and PR-positive and HER-2-negative. Here, ESR1 is linked to neoplasm.